Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

被引：0

作者：

Jing, Yawan ^{[1
,2
]}

Cheng, Ruixin ^{[3
]}

Zeng, Hao ^{[1
]}

Huang, Qin ^{[1
]}

He, Dongyu ^{[1
]}

Sun, Jiayi ^{[1
]}

Tian, Panwen ^{[1
,4
]}

Li, Yalun ^{[1
,4
]}

机构：

[1] Sichuan Univ, Inst Resp Hlth & Multimorbid, Dept Pulm & Crit Care Med, State Key Lab Resp Hlth & Multimorbid,Inst Resp Hl, Chengdu, Sichuan, Peoples R China

[2] Tibet Autonomous Reg Peoples Hosp, Dept Gerontol & Geriatr, Lhasa, Tibet Autonomou, Peoples R China

[3] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Radiat Oncol, Guangzhou 510080, Guangdong, Peoples R China

[4] Sichuan Univ, West China Hosp, Lung Canc Inst, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China

来源：

INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 2024年 / 17卷

基金：

中国国家自然科学基金;

关键词：

non-small cell lung cancer; KRAS G12C mutation; KRAS mutation; immunotherapy; overall survival; KRAS MUTATIONS; KRAS(G12C); IMPACT; DOCETAXEL; SURVIVAL;

D O I：

10.2147/IJGM.S484435

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: KRAS mutation is one of the most common driver oncogenes in non-small cell lung cancer (NSCLC), and the most common mutation subtype is G12C. However, there is still a lack of efficacy and prognosis data related to immunotherapy, which hinders the promotion of new strategies. Methods: Clinical characteristics and treatment outcomes were collected and analyzed for patients with NSCLC harboring KRAS Results: Among the 231 patients with KRAS-mutated NSCLC, 29.4% had KRAS G12C mutations. Compared to the KRAS non-G12C NSCLC group, the KRAS G12C NSCLC group had a greater number of pack-years. The programmed death ligand 1 expression and the proportion of patients with a high tumor mutational burden were not significantly different between the two groups. Similar patterns of TP53, STK11, and CDKN2A mutations were observed between KRAS G12C and KRAS non-G12C NSCLC groups. The median progression-free survival (PFS) (8.4 vs 7.0 months, p=0.100) and overall survival (OS) (12.1 vs 18.1 months, p=0.590) were not statistically different between KRAS G12C and KRAS non-G12C. Compared to patients with KRAS G12C NSCLC who did not receive immunotherapy, patients who received immunotherapy had a better objective response rate (46.2% vs 0%, p=0.002), PFS (12.2 vs 7.5 months, p=0.087) and OS (49.9 vs 11.1 months, p=0.12). Conclusion: Patients with KRAS G12C were more likely to be smokers. Advanced KRAS G12C NSCLC patients who received immunotherapy had a better ORR than those who did not, suggesting that patients with G12C mutations are more likely to benefit from immunotherapy.

引用

页码：4507 / 4517

页数：11

共 33 条

[1] Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Rizvi, Hira ;

Plodkowski, Andrew J. ;

Hellmann, Matthew D. ;

Knezevic, Andrea ;

Heller, Glenn ;

Yu, Helena A. ;

Ladanyi, Marc ;

Kris, Mark G. ;

Arcila, Maria E. ;

Rudin, Charles M. ;

Lito, Piro ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2021, 27 (08) :2209-2215

[2] Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes [J].

Aredo, Jacqueline, V ;

Padda, Sukhmani K. ;

Kunder, Christian A. ;

Han, Summer S. ;

Neal, Joel W. ;

Shrager, Joseph B. ;

Wakelee, Heather A. .

LUNG CANCER, 2019, 133 :144-150

[3] Acquired Resistance to KRASG12C Inhibition in Cancer [J].

Awad, M. M. ;

Liu, S. ;

Rybkin, I. I. ;

Arbour, K. C. ;

Dilly, J. ;

Zhu, V. W. ;

Johnson, M. L. ;

Heist, R. S. ;

Patil, T. ;

Riely, G. J. ;

Jacobson, J. O. ;

Yang, X. ;

Persky, N. S. ;

Root, D. E. ;

Lowder, K. E. ;

Feng, H. ;

Zhang, S. S. ;

Haigis, K. M. ;

Hung, Y. P. ;

Sholl, L. M. ;

Wolpin, B. M. ;

Wiese, J. ;

Christiansen, J. ;

Lee, J. ;

Schrock, A. B. ;

Lim, L. P. ;

Garg, K. ;

Li, M. ;

Engstrom, L. D. ;

Waters, L. ;

Lawson, J. D. ;

Olson, P. ;

Lito, P. ;

Ou, S. -H. I. ;

Christensen, J. G. ;

Janne, P. A. ;

Aguirre, A. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) :2382-2393

[4] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) [J].

Blumenschein, G. R., Jr. ;

Smit, E. F. ;

Planchard, D. ;

Kim, D. -W. ;

Cadranel, J. ;

De Pas, T. ;

Dunphy, F. ;

Udud, K. ;

Ahn, M. -J. ;

Hanna, N. H. ;

Kim, J. -H. ;

Mazieres, J. ;

Kim, S. -W. ;

Baas, P. ;

Rappold, E. ;

Redhu, S. ;

Puski, A. ;

Wu, F. S. ;

Jaenne, P. A. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :894-901

[5] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity [J].

Canon, Jude ;

Rex, Karen ;

Saiki, Anne Y. ;

Mohr, Christopher ;

Cooke, Keegan ;

Bagal, Dhanashri ;

Gaida, Kevin ;

Holt, Tyler ;

Knutson, Charles G. ;

Koppada, Neelima ;

Lanman, Brian A. ;

Werner, Jonathan ;

Rapaport, Aaron S. ;

San Miguel, Tisha ;

Ortiz, Roberto ;

Osgood, Tao ;

Sun, Ji-Rong ;

Zhu, Xiaochun ;

McCarter, John D. ;

Volak, Laurie P. ;

Houk, Brett E. ;

Fakih, Marwan G. ;

O'Neil, Bert H. ;

Price, Timothy J. ;

Falchook, Gerald S. ;

Desai, Jayesh ;

Kuo, James ;

Govindan, Ramaswamy ;

Hong, David S. ;

Ouyang, Wenjun ;

Henary, Haby ;

Arvedson, Tara ;

Cee, Victor J. ;

Lipford, J. Russell .

NATURE, 2019, 575 (7781) :217-+

[6] Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy [J].

Cefali, Marco ;

Epistolio, Samantha ;

Ramelli, Giulia ;

Mangan, Dylan ;

Molinari, Francesca ;

Martin, Vittoria ;

Freguia, Stefania ;

Mazzucchelli, Luca ;

Froesch, Patrizia ;

Frattini, Milo ;

Wannesson, Luciano .

JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)

[7] Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial [J].

de Langen, Adrianus Johannes ;

Johnson, Melissa L. ;

Mazieres, Julien ;

Dingemans, Anne -Marie C. ;

Mountzios, Giannis ;

Pless, Miklos ;

Wolf, Jurgen ;

Schuler, Martin ;

Lena, Herve ;

Skoulidis, Ferdinandos ;

Yoneshima, Yasuto ;

Kim, Sang-We ;

Linardou, Helena ;

Novello, Silvia ;

van der Wekken, Anthonie J. ;

Chen, Yuanbin ;

Peters, Solange ;

Felip, Enriqueta ;

Solomon, Benjamin J. ;

Ramalingam, Suresh S. ;

Dooms, Christophe ;

Lindsay, Colin R. ;

Ferreira, Carlos Gil ;

Blais, Normand ;

Obiozor, Cynthia C. ;

Wang, Yang ;

Mehta, Bhakti ;

Varrieur, Tracy ;

Ngarmchamnanrith, Gataree ;

Stollenwerk, Bjorn ;

Waterhouse, David ;

Paz-Ares, Luis .

LANCET, 2023, 401 (10378) :733-746

[8] Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers [J].

Dogan, Snjezana ;

Shen, Ronglai ;

Ang, Daphne C. ;

Johnson, Melissa L. ;

D'Angelo, Sandra P. ;

Paik, Paul K. ;

Brzostowski, Edyta B. ;

Riely, Gregory J. ;

Kris, Mark G. ;

Zakowski, Maureen F. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2012, 18 (22) :6169-6177

[9] KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study [J].

Frost, Matilde Grupe ;

Jensen, Kristoffer Jarlov ;

Gotfredsen, Ditte Resendal ;

Sorensen, Anne Mette Skov ;

Ankarfeldt, Mikkel Zollner ;

Louie, Karly S. ;

Sroczynski, Nicholas ;

Jakobsen, Erik ;

Andersen, Jon Lykkegaard ;

Jimenez-Solem, Espen ;

Petersen, Tonny Studsgaard .

LUNG CANCER, 2023, 178 :172-182

[10] Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study [J].

Garcia, Betzabel N. Cajiao ;

van Kempen, Leon C. ;

Kuijpers, Chantal C. H. J. ;

Schuuring, Ed ;

Willems, Stefan M. ;

van der Wekken, Anthonie J. .

LUNG CANCER, 2022, 167 :1-7

← 1 2 3 4 →